| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.58 | 0.03 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.38 | 0.2 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.23 | 0.2 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.21 | 0.5 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.19 | 0.3 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | -0.18 | 0.2 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.18 | 0.0006 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.17 | 0.3 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 0.2 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.15 | 0.3 |